Volume 3, Issue 4 (November 2024)
Health Science Monitor 2024, 3(4): 292-297 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Samadi Aidenloo N, Motarjemizadeh Q, Hasani Shayan S. Ocular complications in thalassemia major patients treated with deferoxamine: a hospital-based, cross-sectional study. Health Science Monitor 2024; 3 (4) :292-297
URL: http://hsm.umsu.ac.ir/article-1-165-en.html
URL: http://hsm.umsu.ac.ir/article-1-165-en.html
Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Abstract: (15 Views)
Background & Aims: β-thalassemia is a severe hereditary disorder caused by defective globin synthesis. Patients suffering from β-thalassemia major require regular blood transfusion therapy to survive. Sight-threatening ocular abnormalities are quite common among these patients. This study was planned to evaluate the prevalence of ocular complications in multi-transfused patients with β-thalassemia who have been receiving deferoxamine.
Materials & Methods: Thirty thalassemic patients receiving deferoxamine were studied in this cross-sectional descriptive study. All eligible subjects underwent an ophthalmologic examination, including the Humphrey visual field test, measurement of central corneal thickness (CCT), best-corrected visual acuity (BCVA), and central macular thickness (CMT).
Results: Visual field defects were the most prevalent ocular abnormalities, observed in 50% of the studied subjects. Other ocular changes were as follows: bilateral cortical cataract (10%), macular pigmentary stippling (6.7%), punctate cortical opacity (3.3%), nuclear sclerosis cataract (3.3%), and macular pigmentary mottling (3.3%).
Conclusion: The occurrence of ocular problems is common among thalassemic patients which necessitates long-term follow-up and regular ophthalmologic examination for these patients.
Materials & Methods: Thirty thalassemic patients receiving deferoxamine were studied in this cross-sectional descriptive study. All eligible subjects underwent an ophthalmologic examination, including the Humphrey visual field test, measurement of central corneal thickness (CCT), best-corrected visual acuity (BCVA), and central macular thickness (CMT).
Results: Visual field defects were the most prevalent ocular abnormalities, observed in 50% of the studied subjects. Other ocular changes were as follows: bilateral cortical cataract (10%), macular pigmentary stippling (6.7%), punctate cortical opacity (3.3%), nuclear sclerosis cataract (3.3%), and macular pigmentary mottling (3.3%).
Conclusion: The occurrence of ocular problems is common among thalassemic patients which necessitates long-term follow-up and regular ophthalmologic examination for these patients.
Type of Study: Research |
Subject:
Special
Received: 2024/02/24 | Accepted: 2024/07/20 | Published: 2024/11/20
Received: 2024/02/24 | Accepted: 2024/07/20 | Published: 2024/11/20
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
